Sonic Incytes Medical has developed the VELACUR™ technology, an advanced AI-guided 3D S-WAVE ultrasound elastography device designed for the assessment of liver disease at the point of care. This innovative device measures critical indicators of fatty liver disease, including liver stiffness and attenuation, which are essential for diagnosing conditions such as Metabolic Associated Steatotic Liver Disease (MASLD). The VELACUR system utilizes 3D Shear Wave Absolute Vibro-Elastography (S-WAVE) technology, allowing for deeper measurements and larger tissue samples—offering twice the depth and thirty times the volume compared to traditional transient elastography methods. 

The VELACUR procedure is designed to be quick, comfortable, and non-invasive, making it accessible for trained medical professionals without requiring extensive sonography experience. The process involves activating shear waves, sweeping a probe to collect measurements, and reviewing real-time results, which facilitates immediate patient consultation. With its lower upfront costs and higher reimbursement potential, VELACUR presents a superior economic option for healthcare providers, enhancing the affordability and accessibility of liver imaging. The technology is particularly beneficial for challenging cases, including those involving patients with higher body mass indices (BMI).

Canada

Sonic Incytes is committed to enhancing patient care through innovative diagnostic solutions. The company's flagship product, Velacur™, equips physicians with an advanced liver imaging tool to help manage the growing epidemic of fatty liver disease. Velacur offers real-time, AI guided quantification of the two key markers for fatty liver disease: liver stiffness and attenuation. With real-time results, a low up-front cost and AI guidance, VELACUR makes liver imaging at the point of care affordable and accessible.

Sonic Incytes Medical

Company Details